[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wuhan Createrna Science and Technology Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":170},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,64,82,102,123,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100526413","phase-2-study-of-safety-and-efficacy-of-my008211a-in-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-100526413",false,"NCT06134414","Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","A Multi-center, Randomized, Parallel, Open-label Clinical Phase II Study, to Evaluate the Efficacy and Safety of MY008211A in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients With Signs of Active Hemolysis","Inclusion Criteria:\n\n* Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg\u002Fm2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size ≥ 10%.\n* Mean hemoglobin level \\\u003C100 g\u002FL.\n* LDH \\> 1.5 x Upper Limit of Normal (ULN).\n* Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given.\n\nExclusion Criteria:\n\n* Patients with reticulocytes \\\u003C100x10\\^9\u002FL; platelets \\\u003C30x10\\^9\u002FL; neutrophils \\\u003C0.5x10\\^9\u002FL.\n* Were using a complement inhibitor before the first administration of MY008211A tablets or had discontinued a previous complement inhibitor for less than five half-lives or 120 days, whichever was the longest.\n* History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.\n* Known or suspected hereditary complement deficiency.\n* Previous bone marrow or hematopoietic stem cell transplantation.\n* Previous splenectomy.\n* A history of malignancy within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.",[27],"Paroxysmal Nocturnal Hemoglobinuria (PNH)","NOT_YET_RECRUITING","2025-07-27",{"date":31,"type":32},"2025-07-29","ACTUAL",{"date":34,"type":21},"2025-12",{"date":36,"type":21},"2027-12",{"name":38,"class":39},"Wuhan Createrna Science and Technology Co., Ltd","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100587773","phase-3-study-of-safety-and-efficacy-of-my008211a-in-paroxysmal-nocturnal-hemoglobinuria-pnh-patients-who-are-naive-to-complement-inhibitor-therapy-100587773","NCT06932744","Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy","A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of MY008211A Tablets in PNH Patients Who Are Naive to Complement Inhibitor Therapy","Inclusion Criteria:\n\n1. Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg\u002Fm2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size ≥ 10%.\n2. Mean hemoglobin level \\\u003C100 g\u002FL at screening.\n3. LDH \\> 1.5 x Upper Limit of Normal (ULN) at screening.\n4. Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given.\n\nExclusion Criteria:\n\n1. Patients with reticulocytes \\\u003C100x10\\^9\u002FL; platelets \\\u003C30x10\\^9\u002FL; neutrophils \\\u003C0.5x10\\^9\u002FL.\n2. History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus.\n3. Known or suspected hereditary complement deficiency.\n4. Previous bone marrow or hematopoietic stem cell transplantation.\n5. Previous splenectomy.\n6. A history of malignancy within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.",{"count":48,"type":21},66,[50],"PHASE3","The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.",[53],"Paroxysmal Nocturnal Haemoglobinuria (PNH)","RECRUITING","2025-05-05",{"date":57,"type":32},"2025-05-09",{"date":59,"type":32},"2024-08-30",{"date":61,"type":21},"2025-12-30",{"name":38,"class":39},2,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":80,"locationsCount":81},"100587752","phase-3-study-of-safety-and-efficacy-of-my008211a-in-patients-with-residual-anemia-despite-anti-c5-antibody-treatment-100587752","NCT06932471","Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","A Multicenter, Single-arm, Open-label Phase III Study to Evaluate Efficacy and Safety of MY008211A Tablets in Patients With PNH and Residual Anemia, Despite Treatment With Anti-C5 Antibody.","Inclusion Criteria:\n\n1. Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg\u002Fm2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size ≥ 10%.\n2. Stable regimen of anti-C5 antibody treatment for at least 6 months before treatment, and Hb was still \\\u003C 100 g\u002FL.\n3. The average hemoglobin level of at least two tests in 4 months before screening \\\u003C 100 g\u002FL.\n4. The average hemoglobin level of two tests in the central laboratory during screening \\\u003C 100 g\u002FL.\n5. Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given.\n\nExclusion Criteria:\n\n1. Patients with reticulocytes \\\u003C100x10\\^9\u002FL; platelets \\\u003C30x10\\^9\u002FL; neutrophils \\\u003C0.5x10\\^9\u002FL.\n2. History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus.\n3. Known or suspected hereditary complement deficiency.\n4. Previous bone marrow or hematopoietic stem cell transplantation.\n5. Previous splenectomy.\n6. A history of malignancy within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.",{"count":72,"type":21},20,[50],"The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.",[76],"Paroxysmal Nocturnal Hemoglobinuria",{"date":57,"type":32},{"date":59,"type":32},{"date":61,"type":21},{"name":38,"class":39},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":81},"100587863","phase-2-long-term-safety-and-tolerability-of-my008211a-tablets-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-100587863","NCT06933914","Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria","An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of MY008211A Tablets in Patients With PNH Paroxysmal Nocturnal Hemoglobinuria (PNH)","Inclusion Criteria:\n\n1. Patients who have previously received and completed MY008211A study treatment, and are judged by the investigator to have treatment benefit and may benefit from continued treatment of MY008211A.\n2. Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections.\n\nExclusion Criteria:\n\n1. History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.\n2. Known or suspected hereditary complement deficiency.\n3. Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.",{"count":90,"type":21},120,[24,50],"This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.",[27],"2025-04-11",{"date":96,"type":32},"2025-04-18",{"date":98,"type":32},"2024-11-30",{"date":100,"type":21},"2026-12-30",{"name":38,"class":39},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":81},"100571186","phase-3-qr12000-compound-tablets-in-patients-with-moderate-to-severe-essential-hypertension-100571186","NCT06716970","QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","A Multicenter, Randomized, Double-blind, and Active-controlled Parallel Study to Evaluate the Efficacy and Safety of QR12000 Compound Tablets and Sacubitril\u002Fvalsartan Tablets in Patients with Moderate to Severe Essential Hypertension","Inclusion Criteria:\n\n1. Subjects who can understand and are willing to complying with protocol requirement and sign the informed consent form.\n2. Man or woman aged 18 years to 75 years (inclusive), with BMI≤30 kg\u002Fm2.\n3. Patients with moderate to severe hypertension. Untreated patients must have an msSBP ≥ 160 mmHg and \\\u003C 190 mmHg at the screening and randomization visit; Treated patients must have an msSBP≥150 mmHg and \\\u003C180 mmHg or msSBP≥140 mmHg and \\\u003C170 mmHg at the screening visit based on numbers of antihypertensive and msSBP≥160 mmHg \\\u003C190 mmHg at the randomization visit; Patients must have an absolute difference of ≤20 mmHg in msSBP between randomization visit and the immediately preceding visit.\n4. Subjects who agree to use adequate contraception from 2 weeks prior to screening to 1 month after last dose.\n\nExclusion Criteria:\n\n1. History or evidence of a secondary form of hypertension.\n2. History of peripheral arterial occlusive disease and Raynaud's syndrome.\n3. History of hyperthyroidism.\n4. History of hypotension.\n5. History of angioedema, drug-related or otherwise.\n6. Suffered by severe cerebrovascular disease within 1 year prior to screening.\n7. Suffered by severe heart disease within 1 year prior to screening\n8. History of severe or malignant retinopathy.\n9. History of aortic aneurysm or dissection, cardiac surgery, or percutaneous coronary intervention within 1 year prior to screening.\n10. History of malignant tumor within 5 years prior to screening.\n11. Poorly controlled diabetes prior to screening\n12. History of severe autoimmune diseases.\n13. History of severe mental disorder.\n14. Clinically significant laboratory abnormalities.\n15. History of allergy to the test drug, active control drug, or drugs similar to the test drug and positive control drug or related excipients.\n16. Undergone gastrointestinal surgery that could significantly alter drug absorption, distribution, metabolism, and excretion, or with severe gastrointestinal diseases, dysphagia, or recurrent vomiting that causes difficulty in eating or taking medication.\n17. Intolerance to the run-in period.\n18. Poor medication compliance or other non-compliance during run-in period.\n19. Participated in any interventional clinical trial within 3 months prior to screening, plan to participate in another clinical trial during the period of this trial, or plan to participate in another clinical trial within 1 month after the end of this trial.\n20. History of alcohol abuse within 6 months prior to screening or evidence of drug abuse.\n21. Not agree or unable to comply with the restrictions on concomitant treatment during the study.\n22. Pregnancy test positive, lactating women, or women planning to become pregnant.\n23. High-altitude workers or large motor vehicle drivers and other professionals engaged in hazardous mechanical operations.\n24. Other conditions that by the investigator's discretion may interfere with efficacy or safety assessment of the study, or pose a great risk to the subject.",{"count":110,"type":21},810,[50],"The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril\u002Fvalsartan 200mg in patients with moderate to severe essential hypertension.",[114],"Essential Hypertension","2024-12-03",{"date":117,"type":32},"2024-12-06",{"date":119,"type":21},"2024-12-30",{"date":121,"type":21},"2027-02-28",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":81},"100568895","phase-2-study-to-evaluate-the-efficacy-and-safety-of-my008211a-in-subjects-with-primary-immunoglobulin-a-nephropathy-igan-100568895","NCT06687174","Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)","Inclusion Criteria:\n\n1. Males or females ≥ 18 and ≤ 75 years of age at Screening.\n2. Estimated GFR(eGFR) ≥30 mL\u002Fmin\u002F1.73m2.\n3. Subjects with a biopsy-confirmed diagnosis of IgAN.\n4. Urine protein ≥0.75 g\u002F24h from a 24h urine collection.\n5. All patients must have been on stable supportive care including a maximally tolerated dose or approved maximal dose of ACEi or ARB therapy for at least 90 days prior to the first administration of study drug.\n6. Subjects who received SGLT2i must have been on a stable treatment with the maximum allowed or tolerated dose prior to the first administration of study drug.\n7. Vaccination against Neisseria meningitidis(MenACWY) is required within 3 years.\n8. Vaccination for the prevention of S. pneumoniae is required within 5 years.\n\nExclusion Criteria:\n\n1. Systolic blood pressure \\>130 mm Hg or diastolic blood pressure \\>80 mm Hg.\n2. Presence of any secondary IgAN.\n3. Presence of rapidly progressive glomerulonephritis.\n4. Presence of other chronic kidney diseases.\n5. Patients with a diagnosis of type 1 or type 2 diabetes mellitus.\n6. A history of invasive infections caused by encapsulated bacteria, e.g., meningococci or pneumococci.\n7. Patients previously treated with immunosuppressive agents exposure within 90 days prior to start of study drug dosing.\n8. Patients previously treated with traditional Chinese medicine containing immunosuppressive ingredients within 90 days prior to start of study drug dosing.\n9. Patients who had been treated with any systemic corticosteroids within the 180 days before treatment ≥20 mg\u002Fd for primary IgAN indication.\n10. Patients who previously have received biologic agent or monoclonal antibodies prior to start of study drug dosing within 5 half-lives or 30 days (whichever is longer).\n11. Patients who have received live\u002Fattenuated vaccines within the 4 weeks prior to randomization, or plan to receive during the trial.",{"count":131,"type":21},72,[24],"Efficacy and safety of MY008211A in IgAN patients",[135],"IgA Nephropathy (IgAN)",[137,138],"kidney disease","Primary glomerular disease","2024-11-13",{"date":141,"type":32},"2024-11-18",{"date":143,"type":21},"2024-12-31",{"date":145,"type":21},"2028-01-31",{"name":38,"class":39},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":154,"sex":16,"minAge":17,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":81},"100557849","phase-1-to-evaluate-the-effect-of-single-oral-dose-of-my008211a-tablets-on-qtc-interval-in-healthy-subjects-100557849","NCT06543459","To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects","A Single-center, Randomized, Double-blind, Single Oral Dose, Placebo-controlled Study to Evaluate the Effect of MY008211A Tablets on QTc Interval in Healthy Chinese Adult Subjects","Inclusion Criteria:\n\n1. Volunteers must be fully informed of this study and the content, process of the study and possible adverse events related to experimental drug will be fully understood, and voluntarily signed a written Informed Consent Form (ICF);\n2. 18≤ age ≤ 45 years old, male or female Chinese adult volunteers;\n3. Body weight: ≥50 kg for male, ≥45 kg for female; body mass index (BMI): 19.0-26.0 kg\u002Fm2 (inclusive) at screening;\n4. Volunteers should be able to communicate well with the investigator, understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. The investigator judges that there are other disease or medical conditions that are clinical significant or may prevent the volunteer from following the study protocol and completing the study, abnormal including but not limited to central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, immune system, mental system, endocrine and metabolic system;\n2. Volunteers with chronic or active gastrointestinal diseases such as esophageal disease, gastritis, gastric ulcer, enteritis, active gastrointestinal bleeding, or gastrointestinal surgery within the past three years and judged by the investigator to have clinical significance at present;\n3. Volunteers with torsades de pointes (TDP) or other risk factors for malignant arrhythmias, or short QT syndrome, long QT syndrome, sudden unexplained death or drowning in youth (≤ 40 years old), or a family history of a first-degree relative (i.e., biological parent, sibling, or child) of sudden infant death syndrome, or other heart disease that the investigators determined was not suitable for inclusion;\n4. Volunteers with hyperkalemia, hypokalemia, hypermagnesia, hypomagnesemia, hypercalcemia or hypocalcemia and judged by the investigator to have clinical significance;\n5. History of known or suspected immunodeficiency (e.g., history of frequent recurrent infections), inherited or acquired complement deficiency；\n6. Volunteers who underwent surgery within 6 months pre-dose, which judged by the investigator to affect the absorption, distribution, metabolism, and excretion of the experimental drug(e.g. cholecystectomy, except appendicitis surgery); Surgical procedures within 4 weeks pre-dose or planned to undergo a surgical procedure during the trial;\n7. Volunteers who had a clear history of capsular microbial infection within 6 months before screening; Including but not limited to: Streptococcus pneumoniae, Bacillus anthracis, Salmonella, Salmonella typhi, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, Neisseria meningitidis, Haemophilus influenzae, Legionella pneumophila infection history;\n8. Volunteers with previous or current history of TB infection or with positive lymphobacteria culture + interferon test；\n9. Active systemic bacterial, viral, or fungal infection within 14 days pre-dose;\n10. Fever (≥ 38 ℃) within 7 days pre-dose;\n11. Volunteers with a history of clinically significant drug allergy or allergic disease (such as asthma, urticaria, eczematous dermatitis, etc.), or a possible or clear allergy to the experimental drug (including similar drugs) or any excipients thereof as judged by the investigator;\n12. Volunteers with clinical significant examination abnormalities which judged by the investigator such as vital signs, physical examination, routine laboratory tests (can reviewable, including: blood routine, reticulocyte count, procalcitonin + myoglobin, blood biochemical + hypersensitive C-reactive protein, urine routine, coagulation function + plasma D-Dimer determination), chest X-ray, abdominal ultrasound at screening or baseline；\n13. Volunteers with 12-ECG examination and reviewable result such as QTcF≥450 ms or PR interval ≥200ms or QRS wave complex ≥120ms or clinical significant abnormality ECG which judged by the investigator at screening or baseline or pre-dose；\n14. Volunteers who administrated any other clinical study drug or enrolled in any Interventional clinical trial within 3 months before screening；\n15. Volunteers who donated blood or lost blood (≥ 400mL) within 3 months pre-dose, received a blood transfusion or use of blood products within 4 weeks pre-dose, or intended to donate blood or blood components during or within 3 months after study;\n16. Volunteers who had taken any medicine or OTC medicine or Chinese herbal medicine or food supplement (including vitamins, health foods, etc.) other non-drug therapeutic factors that affect drug absorption, distribution, metabolism and excretion;\n17. Volunteers who received a vaccine or live attenuated vaccine within 14 days pre-dose, or who plan to receive a vaccine during the study;\n18. Volunteers with difficulty in blood collection or cannot tolerate intravenous puncture;\n19. Volunteers with a history of drug use or substance abuse or with positive urine drug abuse screening test;\n20. Volunteers with any positive result of virological test;\n21. Volunteers who drink more than 14 units a week (one unit is defined as 360mL of beer or 45mL of liquor or 150mL of wine) within 3 months before screening or with positive result of alcohol breath test or unwillingness to stop drinking alcohol or any alcohol-based product during the study；\n22. Volunteers who smoke more than 5 cigarettes per day(or use a significant amount of nicotine products) within 3 months before screening or will be unable to stop using any tobacco products during the study or with positive result of urine nicotine test；\n23. Volunteers who habitual consumption of grapefruit juice or excessive amounts of tea, coffee and\u002For caffeinated beverages and will be unable to stop use during the study, or consume any food or drink containing chocolate, caffeine, or rich in xanthines within 48h pre-dose；\n24. Volunteers who have special requirements for diet and cannot abide by the uniform diet；\n25. Volunteers (or their partners) who plan to be pregnant or donate sperm or eggs during the study to 3 months after the end of the study, or who are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, condoms, contraceptive rings, surgical sterilization, etc.);\n26. Volunteers of pregnant or lactating women; or having unprotected sex within 2 weeks pre-dose; or oral contraceptive use within 30 days or long-acting estrogen or progestin injectable or implant use within 6 months pre-dose; or with positive blood pregnancy test pre-dose;\n27. Volunteers have other reasons for not fit for participating in the study as judged by the investigator.",true,"45 Years",{"count":157,"type":21},16,[159],"PHASE1","A Concentration-QT Interval Correction (C-QTc) study of MY008211A Tablets in Healthy Subjects",[76],"2024-08-06",{"date":164,"type":32},"2024-08-09",{"date":166,"type":21},"2024-08-10",{"date":168,"type":21},"2024-12-13",{"name":38,"class":39},""]